Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intranasal nalmefene - Opiant Pharmaceuticals

Drug Profile

Intranasal nalmefene - Opiant Pharmaceuticals

Alternative Names: Nalmefene hydrochloride - Opiant Pharmaceuticals; OPNT-003

Latest Information Update: 24 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Opiant Pharmaceuticals
  • Developer National Institute of Drug Abuse; Opiant Pharmaceuticals
  • Class Antidotes; Antipruritics; Antirheumatics; Drug withdrawal therapies; Hepatoprotectants; Morphinans; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid receptor antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid-related disorders

Most Recent Events

  • 01 Jun 2022 Preregistration for Opioid-related disorders in USA (rolling submission) (Intranasal)
  • 01 Jun 2022 Opiant Pharmaceuticals completes pre-NDA meeting with the US FDA before June 2022
  • 01 Jun 2022 Opiant Pharmaceuticals anticipates to complete rolling submission of NDA application in Opioid-related disorders in USA, in the second half of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top